Tan Lab

About 

Work focuses on elucidating the mechanisms by which metabolic disorders and oxidative stress contribute to complications of metabolic syndrome and chemotherapy-associated cardiovascular toxicity. He is also developing novel therapeutic strategies targeting growth factors and their receptors—including SDF-1, CXCR4, CXCR7, FGF1, FGF5, FGF9, FGF16, and FGF21—with an emphasis on designing receptor agonists and antagonists that activate multiple beneficial effectors (such as MT, Nrf2, and AMPK) to promote redox homeostasis, metabolic reprogramming, cell survival and function, and tissue repair.

Key Research Areas

  • The roles of the SDF-1/CXCR4/CXCR7 axis in metabolic syndrome–related complications and chemotherapy-induced cardiovascular toxicity.
  • The roles of fibroblast growth factors (FGFs; e.g., FGF1, FGF5, FGF9, FGF16, FGF21) in metabolic syndrome–related complications and chemotherapy-induced cardiovascular toxicity.
  • The antioxidative and metabolic mechanisms mediated by metallothionein, Nrf2, and AMPK in metabolic syndrome–related complications and chemotherapy-induced cardiovascular toxicity.

Team 

Recent Publications

Tan Lab

School of Medicine/Pediatrics

Website about

Phone

Location

Baxter 1 Building, Room 304